Pharmacokinetics and pharmacodynamics of peginterferon beta‐1a in patients with relapsing‐remitting multiple sclerosis in the randomized ADVANCE study-Reference-Cited by-同舟云学术

Pharmacokinetics and pharmacodynamics of peginterferon beta‐1a in patients with relapsing‐remitting multiple sclerosis in the randomized ADVANCE study

Published:2015-02-20 Issue:3 Volume:79 Page:514-522
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Hu Xiao¹,Cui Yue¹,White Joleen¹,Zhu Ying¹,Deykin Aaron¹,Nestorov Ivan¹,Hung Serena¹

Affiliation:

1. Biogen Idec Inc. Cambridge MA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.12521

Reference20 articles.

1. 2014 Biogen Idec Inc. Cambridge MA Plegridy (peginterferon beta‐1a) Package Insert

2. 2014 Biogen Idec Inc. Maidenhead Berkshire UK Plegridy (Peginterferon beta‐1a) Package Insert

3. A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology

4. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

5. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-01-04

2. Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study;Med;2022-09

3. Pharmacokinetics/pharmacodynamics by Race: Analysis of a Peginterferon β-1a Phase I Study;2022-04-03

4. Avances y perspectivas actuales en recursos y estrategias terapéuticas: fármacos biológicos;Medicine - Programa de Formación Médica Continuada Acreditado;2021-05

5. Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers;Therapeutic Advances in Neurological Disorders;2021-01